CRIS
Curis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Stock Price Surged Significantly
High Gross Profit Margin
Gap Up
EPS Below Expectations
Revenue Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRIS
Curis, Inc.
A biotechnology company that developing innovative therapeutics for the treatment of cancer
128 Spring Street, Building C - Suite 500, Lexington, Massachusetts, 02421
--
Curis, Inc., was incorporated as a Delaware corporation in February 2000. The company is a biotechnology company focused on the development of emavusertib, an oral, small-molecule inhibitor of the interleukin -1 receptor-associated kinase.
Earnings Call
Q2/2025
Estimate EPS-1.51
Actual EPS-0.68
Estimate Revenue2.64M
Actual Revenue2.75M
Curis, Inc. Q2 2025: Unraveling Contradictions in Enrollment Strategy, FDA Dynamics, and PCNSL Data Expectations
Aug 05,2025 11:38
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CRIS has released its 2025 Q3 earnings. EPS was reported at -0.49, versus the expected -0.6, beating expectations. The chart below visualizes how CRIS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRIS has released its 2025 Q3 earnings report, with revenue of 3.18M, reflecting a YoY change of 8.36%, and net profit of -7.73M, showing a YoY change of 23.41%. The Sankey diagram below clearly presents CRIS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
